Likes Subject Whalatane 11/03/22 2:30 PM
HC Wainwright & Co. Maintains Buy on Kezar Whalatane 08/12/22 11:48 AM
Kezar is reporting an unaudited cash position of Whalatane 07/11/22 4:56 PM
I covered the other day at $7.75. Just HokieHead 06/30/22 10:06 PM
Well sell the news … something I usually Whalatane 06/30/22 9:44 PM
Shorted 1,500 at $11.20 premarket, still holding for HokieHead 06/28/22 4:52 PM
Boy what timing on buying 2m more shares G2G 06/28/22 3:40 PM
It was a P 2 trial and there Whalatane 06/28/22 12:45 PM
Congratulations KZR on their phase 1B open label, nferna 06/28/22 7:44 AM Whalatane 06/27/22 11:14 PM
New position disclosed in KZR...Israel Englander Whalatane 06/27/22 12:37 PM
Kezar Life Sciences (KZR)...from TipRanks Whalatane 03/24/22 11:36 AM
Large open market purchase by a director Whalatane 03/23/22 10:15 AM
Still think this is a crap stock Ganz Whalatane 03/18/22 12:54 PM
Compare AUPH to KZR in this sell off . Whalatane 01/24/22 3:00 PM
Buy some AUPH if you want some returns Ganz 01/11/22 12:35 PM
This is a crap stock Ganz 01/11/22 12:35 PM
ONLY 2 DRUGS LOSING 60 MILLION A YEAR Stockexpertpro 11/16/21 11:47 AM
WARRANTS FOR .0001 FOR SHARES YUCK NO REVENUES Stockexpertpro 11/16/21 11:32 AM
KZR - Monday Rundown, Tuesday Expectations Jake L 11/15/21 11:20 PM
over 3,000 OTM calls with expiry this Friday Cosa 11/15/21 6:36 PM
* * $KZR Video Chart 06-04-2020 * * ClayTrader 06/04/20 5:54 PM
What can you tell me about this company? Dankshydro 02/12/20 10:57 PM
Opening up this morning. boston127 02/11/20 9:10 AM
Up in AH. Good opening tomorrow. boston127 02/10/20 5:51 PM
This is insane today. boston127 02/10/20 1:54 PM
Nice move today. boston127 02/10/20 11:31 AM
Likes Subject

08/12/22 11:48 AM
06/30/22 10:06 PM
06/30/22 9:44 PM
06/28/22 12:45 PM
03/24/22 11:36 AM
03/23/22 10:15 AM
03/18/22 12:54 PM
01/24/22 3:00 PM
01/11/22 12:35 PM
11/16/21 11:47 AM
11/16/21 11:32 AM
06/04/20 5:54 PM
02/12/20 10:57 PM
02/11/20 9:10 AM
02/10/20 5:51 PM
02/10/20 1:54 PM
02/10/20 11:31 AM

Kezar Life Sciences Inc (KZR)

Posts (Today)
Posts (Total)
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants
5:50 PM ET 2/4/20 | GlobeNewswire
Related Quotes
11:32 AM ET 2/10/20
Symbol Last % Chg
4.43 18.77%
Real time quote.

Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the closing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock was $2.60 and the public offering price of each pre-funded warrant was $2.599. In addition, Kezar granted to the underwriters an option to purchase up to an additional 2,850,000 shares of common stock, which the Underwriters exercised in full.

Cowen, Wells Fargo Securities and William Blair acted as joint book-running managers for the offering.

Kezar received gross proceeds of $56.8 million from the offering, before deducting underwriting discounts and offering expenses. Kezar intends to use the net proceeds from the offering primarily to fund the research and development of its product candidates, acquire or license products or technologies that are complementary to its own, although Kezar has no current plans, commitments or agreements with respect to any acquisitions or licenses as of the date hereof, and for working capital and general corporate purposes.

The securities described above were offered by Kezar pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission ("SEC") dated July 3, 2019. A preliminary prospectus supplement and a final prospectus supplement relating to the offering are filed with the SEC and available on the SEC's website at Copies of the preliminary and final prospectus supplements relating to the offering may be obtained by contacting Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; Wells Fargo Securities, LLC Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York 10001, by telephone at (800) 326-5897 or by email at; or William Blair & Company, L.L.C. Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at

Most Liked Posts
(Last 30 Days)
New Post